Advertisement
Home »

Risankizumab Displays Efficacy for Patients With UC

Mar 01, 2024

REFERENCES & ADDITIONAL READING

Schreiber S, et al. Risankizumab maintenance therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 COMMAND study. OP06, 19th Congress of ECCO, February 21-24, 2024, Stockholm, Sweden.

ABOUT THE CONTRIBUTORS

Author

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement